Drugs / Donzakimig
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06716879 | Dec 2024 → Apr 2025 | — | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT05277571 | Mar 2022 → Jul 2025 | atopic eczema | UCB Biopharma SRL | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Donzakimig | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06716879 ↗ |
| Known as | UCB1381 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05277571 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5314824 ↗ |
| Route | Intravenous | “UCB1381 will be administered intravenously (iv) or subcutaneously (sc) in different dosages in Part A and iv in Part B” NCT05277571 ↗ |
| Route | Subcutaneous | “UCB1381 will be administered intravenously (iv) or subcutaneously (sc) in different dosages in Part A and iv in Part B” NCT05277571 ↗ |